PH3 Study of WWO V940 in NSCLC for patients with doublet chemo followed by surgery
Phase III Clinical Trial
Protocol Title: A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009) (V940-009)
Participating Locations